Rhythm Pharmaceuticals is transitioning from a development stage to a commercial rare disease leader, leveraging its IMCIVREE franchise for biologically defined obesity. IMCIVREE’s recent FDA and EU ...

Recent developments in the Prader-Willi syndrome treatment market, including progress on targeted therapies such as Rhythm ...

Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance ...

US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.

Add Yahoo as a preferred source to see more of our stories on Google. Seattle Children's Hospital Seattle Children's said a clinical trial published this week in The New England Journal of Medicine ...

At the recent ObesityWeek ® Interactive 2020 meeting, researchers discussed the investigational agent setmelanotide and it's potential to treat two rare genetic diseases that cause insatiable hunger ...

A new study led by researchers from McMaster University has shown that, while relatively rare in the general population, there are a large number of varied, genetic syndromes associated with obesity.

Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show ...

Although the number of U.S. children under age 12 with obesity who are prescribed the weight-loss drugs Saxenda, Wegovy and Zepbound remains low, it was 310 times higher in June 2026 than in 2019, ...

The obesity market has been transformed by GLP-1 therapies, but the next phase of innovation is increasingly expanding beyond GLP-1 alone. One small biotechnology company positioned at the ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on Wednesday released topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R ...